Fox Reporter Orlando Salinas just reported that physicians they have consulted have told them that taking high doses of the narcotics Rush is alleged to have bought can cause HEARING LOSS
Is the picture becoming clear now?
Or is Fox News part of the "left-wing conspiracy" too?
You Rushbots are unbelievable.
Why don't you use your own noodle instead of parroting someone else's garbage.
Oxycontin Side Effects / Oxycodone HCl
The safety of OxyContin® was evaluated in double-blind clinical trials involving 713 patients with moderate to severe pain of various etiologies. In open-label studies of cancer pain, 187 patients received OxyContin® in total daily doses ranging from 20 mg to 640 mg per day. The average total daily dose was approximately 105 mg per day. Serious adverse reactions which may be associated with OxyContin® (oxycodone hydrochloride controlled-release) tablet therapy in clinical use are those observed with other opioid analgesics, including respiratory depression, apnea, respiratory arrest, and (to an even lesser degree) circulatory depression, hypotension, or shock (see OXYCONTIN OVERDOSE). The non-serious adverse events seen on initiation of therapy with OxyContin® are typical opioid side effects. These events are dose-dependent, and their frequency depends upon the dose, the clinical setting, the patient s level of opioid tolerance, and host factors specific to the individual. They should be expected and managed as a part of opioid analgesia. The most frequent (>5%) include: constipation, nausea, somnolence, dizziness, vomiting, pruritus, headache, dry mouth, sweating, and asthenia. In many cases the frequency of these events during initiation of therapy may be minimized by careful individualization of starting dosage, slow titration, and the avoidance of large swings in the plasma concentrations of the opioid. Many of these adverse events will cease or decrease in intensity as OxyContin® therapy is continued and some degree of tolerance is developed. Clinical trials comparing OxyContin® with immediate-release oxycodone and placebo revealed a similar adverse event profile between OxyContin® and immediate-release oxycodone. The most common adverse events (>5%) reported by patients at least once during therapy were:
The following adverse experiences were reported in OxyContin® treated patients with an incidence between 1% and 5%. In descending order of frequency they were anorexia, nervousness, insomnia, fever, confusion, diarrhea, abdominal pain, dyspepsia, rash, anxiety, euphoria, dyspnea, postural hypotension, chills, twitching, gastritis, abnormal dreams, thought abnormalities, and hiccups. The following adverse reactions occurred in less than 1% of patients involved in clinical trials or were reported in post marketing experience: General: accidental injury, chest pain, facial edema, malaise, neck pain, pain. Opioid analgesics, including OxyContin®, may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression. Oxycodone is metabolized in part to oxymorphone via cytochrome P450 2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs including amiodarone and quinidine as well as polycyclic antidepressants), such blockade has not yet been shown to be of clinical significance with this agent. Clinicians should be aware of this possible interaction, however. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hearing loss must be a new side-effect.